The in vivo experiment showed that PTBP3 knockdown significantly inhibited HuPBMC tumor growth and improved immunotherapeutic sensitivity in gallbladder cancer, as measured by subcutaneous tumor volume and mass (Figure 3F–H; Figure S3H, Supporting Information). This evidence concerns the gene PTBP3 and gallbladder cancer.